ERBB2 and gastric cancer: Nevertheless, HER-2 overexpression exists in 10–30% gastric cancer patients, in which mutant HER-2 occurs in 5% gastric cancer cases, and is more prevalent in 7% microsatellite instability cases and 12% EBV-positive ones (132).